Hemorrhagic transformation (HT) critically impacts outcomes in acute ischemic stroke (AIS) patients post-endovascular thrombectomy (EVT). Building upon the validated utility of post-EVT dual-energy CT (DECT), this study focused on developing and integrating a DECT-based predictive model with key clinical variables to achieve precise, individualized quantification of HT risk. This retrospective study analyzed 116 thrombectomy treated AIS patients stratified by HT status. Post-EVT DECT within 24 h assessed CT values (in Hounsfield Units, HU) of ischemic lesions on mixed energy images; CT values (in HU) on virtual non-contrast (VNC) images and on Sn80 keV and Sn150 keV monoenergetic images; absolute iodine concentrations (AIC, in mg/mL); and relative iodine concentrations (RIC, in %, where RIC = lesion AIC/sigmoid sinus AIC), using follow-up imaging and clinical criteria as the gold standard for HT.. HT patients exhibited higher NIHSS (median 14.5 vs. 9.0) and lower ASPECTS (9 vs. 13) than non-HT (nHT) counterparts, with elevated glucose (GLU, 8.26 vs. 6.45 mmol/L) and lower systolic blood pressure (SBP, 147.5 vs. 156.5 mmHg) (all P < 0.050). DECT-derived parameters demonstrated diagnostic utility, with both iodine overlay maps (IOM) and VNC positivity (χ² = 60.331, P < 0.001) and dual negativity (χ² = 58.870, P < 0.001) showing significant intergroup discrimination. Among 42 patients with IOM hyperdensity, RIC differed significantly between subgroups (t = - 2.566, P = 0.014), with elevated RIC independently associated with HT risk (OR = 1.040, 95% CI 1.003-1.078; P = 0.034). RIC alone exhibited strong predictive capacity for HT (AUC = 0.890, 95% CI 0.822-0.957). A nomogram-based model incorporating NIHSS, ASPECTS, and RIC achieved excellent HT prediction in both training (AUC = 0.947, 95% CI 0.903-0.991) and validation cohorts (AUC = 0.902, 95% CI 0.786-1.000), with stable calibration (training: P = 0.655; validation: P = 0.175) and clinical utility on decision curve analysis. Integration into stroke protocols may guide anticoagulation and secondary prevention decisions.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: